HRP20131164T1 - Delta kristalni oblik argininske soli perindoprila, postupak za njegovu pripremu i farmaceutske pripravke koji ga sadrže - Google Patents
Delta kristalni oblik argininske soli perindoprila, postupak za njegovu pripremu i farmaceutske pripravke koji ga sadrže Download PDFInfo
- Publication number
- HRP20131164T1 HRP20131164T1 HRP20131164AT HRP20131164T HRP20131164T1 HR P20131164 T1 HRP20131164 T1 HR P20131164T1 HR P20131164A T HRP20131164A T HR P20131164AT HR P20131164 T HRP20131164 T HR P20131164T HR P20131164 T1 HRP20131164 T1 HR P20131164T1
- Authority
- HR
- Croatia
- Prior art keywords
- crystalline form
- compound
- expressed
- formula
- pharmaceutical preparation
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 6
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 title claims 2
- 229960002582 perindopril Drugs 0.000 title claims 2
- 238000002360 preparation method Methods 0.000 title claims 2
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 7
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 3
- 229910052802 copper Inorganic materials 0.000 claims 3
- 239000010949 copper Substances 0.000 claims 3
- 229940093499 ethyl acetate Drugs 0.000 claims 3
- 235000019439 ethyl acetate Nutrition 0.000 claims 3
- 238000000634 powder X-ray diffraction Methods 0.000 claims 3
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 2
- 239000000480 calcium channel blocker Substances 0.000 claims 2
- 239000002934 diuretic Substances 0.000 claims 2
- 230000001882 diuretic effect Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 125000002059 L-arginyl group Chemical class O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 229960000528 amlodipine Drugs 0.000 claims 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims 1
- 208000037849 arterial hypertension Diseases 0.000 claims 1
- 238000001875 carbon-13 cross-polarisation magic angle spinning nuclear magnetic resonance spectrum Methods 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 claims 1
- 229960004569 indapamide Drugs 0.000 claims 1
- ACRHBAYQBXXRTO-OAQYLSRUSA-N ivabradine Chemical compound C1CC2=CC(OC)=C(OC)C=C2CC(=O)N1CCCN(C)C[C@H]1CC2=C1C=C(OC)C(OC)=C2 ACRHBAYQBXXRTO-OAQYLSRUSA-N 0.000 claims 1
- 229960003825 ivabradine Drugs 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 238000001953 recrystallisation Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B43/00—Forming, feeding, opening or setting-up containers or receptacles in association with packaging
- B65B43/42—Feeding or positioning bags, boxes, or cartons in the distended, opened, or set-up state; Feeding preformed rigid containers, e.g. tins, capsules, glass tubes, glasses, to the packaging position; Locating containers or receptacles at the filling position; Supporting containers or receptacles during the filling operation
- B65B43/46—Feeding or positioning bags, boxes, or cartons in the distended, opened, or set-up state; Feeding preformed rigid containers, e.g. tins, capsules, glass tubes, glasses, to the packaging position; Locating containers or receptacles at the filling position; Supporting containers or receptacles during the filling operation using grippers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65G—TRANSPORT OR STORAGE DEVICES, e.g. CONVEYORS FOR LOADING OR TIPPING, SHOP CONVEYOR SYSTEMS OR PNEUMATIC TUBE CONVEYORS
- B65G47/00—Article or material-handling devices associated with conveyors; Methods employing such devices
- B65G47/74—Feeding, transfer, or discharging devices of particular kinds or types
- B65G47/90—Devices for picking-up and depositing articles or materials
- B65G47/91—Devices for picking-up and depositing articles or materials incorporating pneumatic, e.g. suction, grippers
- B65G47/912—Devices for picking-up and depositing articles or materials incorporating pneumatic, e.g. suction, grippers provided with drive systems with rectilinear movements only
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C277/00—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C277/08—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups of substituted guanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65G—TRANSPORT OR STORAGE DEVICES, e.g. CONVEYORS FOR LOADING OR TIPPING, SHOP CONVEYOR SYSTEMS OR PNEUMATIC TUBE CONVEYORS
- B65G2201/00—Indexing codes relating to handling devices, e.g. conveyors, characterised by the type of product or load being conveyed or handled
- B65G2201/02—Articles
- B65G2201/0235—Containers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Mechanical Engineering (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (16)
1. Delta kristalni oblik L-argininske soli perindoprila formule (I), naznačen time, da ima slijedeće vrhove izmjereno rentgenskom difrakcijom praha difraktometrom s bakarnom antikatodom izraženim putem Braggovog kuta 2 theta (°) : 4.3, 11.0, 11.1, 13.2, 14.6, 16.0 i 21.9.
[image]
2. Delta kristalni oblik spoja formule (I) prema zahtjevu 1, naznačen time, da ima slijedeće vrhove izmjereno rentgenskom difrakcijom praha difraktometrom s bakarnom antikatodom izraženim putem Braggovog kuta 2 theta (°): 4.3, 11.0, 11.1, 11.9, 12.5, 13.2, 14.6, 16.0, 19.2, 19.4, 20.0, 21.9, 22.2 i 22.6.
3. Delta kristalni oblik spoja formule (I) prema zahtjevu 1, naznačen time, da ima slijedeće vrhove izmjereno rentgenskom difrakcijom praha difraktometrom s bakarnom antikatodom i izražena u smislu interplanarnog razmaka, Braggovog kuta 2 theta, i relativnog intenziteta, izraženo kao postotak u odnosu na najintenzivniju liniju.
[image]
4. Delta kristalni oblik spoja formule (I) u skladu s patentnim zahtjevom 1, naznačen time, da u čvrstom stanju 13C CPMAS NMR spektar ima slijedeće pikove, izražena u ppm:
[image]
5. Postupak za pripremu delta kristalnog oblika spoja formule (I) u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time, da je dobiven kristalizacijom ili rekristalizacijom iz binarne smjese acetonitrila, etil-acetata ili metil- terc-butil eter i dimetilsulfoksid ili trojnoj smjesi acetonitrila, dimetil sulfoksida i toluena, na temperaturi višoj od 20°C.
6. Postupak prema zahtjevu 5, naznačen time, da binarna smjesa acetonitrila, etil-acetata ili tert-butil metil etera i dimetilsulfoksida ima omjer acetonitrila/dimetilsulfoksida, etilacetata/dimetilsulfoksida ili metil terc-butil etera/dimetilsulfoksida u rasponu od 90/10 w/w do 10/90 w/w.
7. Postupak u skladu s patentnim zahtjevom 5 ili patentnim zahtjevom 6, naznačen time, da je temperatura medija između 25 i 80°C, uključivo.
8. Postupak u skladu s patentnim zahtjevom 7, naznačen time, da se smjesa zagrijava na temperaturi od 60 do 80°C.
9. Postupak prema bilo kojem od zahtjeva 5 do 8, naznačen time, da se smjesa inokulira u obliku delta kristala.
10. Farmaceutski pripravak, naznačen time, da sadrži, kao aktivni sastojak, spoj prema bilo kojem od zahtjeva 1 do 4, u kombinaciji s jednim ili više inertnih, ne-toksičnih, farmaceutski prihvatljivih nosača.
11. Farmaceutski pripravak prema zahtjevu 10, naznačen time, da također sadrži diuretik, kalcijev antagonist ili inhibitor IF struje.
12. Farmaceutski pripravak prema zahtjevu 11, naznačen time, da je diuretik indapamid.
13. Farmaceutski pripravak prema zahtjevu 11, naznačen time, da je antagonist kalcija amlodipin.
14. Farmaceutski pripravak prema zahtjevu 11, naznačen time, da inhibitor IF struje ivabradin.
15. Spoj prema bilo kojem od zahtjeva 1 do 4, naznačen time, da je namijenjen upotrebi u liječenju kardiovaskularnih bolesti.
16. Spoj prema bilo kojem od zahtjeva 1 do 4, naznačen time, da je namijenjen upotrebi u liječenju arterijske hipertenzije, srčane insuficijencije ili stabilne koronarne bolesti.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1200033A FR2985511B1 (fr) | 2012-01-05 | 2012-01-05 | Forme cristalline delta du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20131164T1 true HRP20131164T1 (hr) | 2014-01-03 |
Family
ID=47427277
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20131164AT HRP20131164T1 (hr) | 2012-01-05 | 2013-12-05 | Delta kristalni oblik argininske soli perindoprila, postupak za njegovu pripremu i farmaceutske pripravke koji ga sadrže |
Country Status (44)
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3050380B1 (fr) | 2016-04-20 | 2020-07-10 | Les Laboratoires Servier | Composition pharmaceutique comprenant un betabloquant, un inhibiteur de l'enzyme de conversion et un antihypertenseur ou un ains. |
CN110283104B (zh) * | 2018-08-22 | 2022-06-14 | 南京济群医药科技股份有限公司 | 一种精氨酸培哚普利的制备方法 |
EP3842035A1 (en) | 2019-12-23 | 2021-06-30 | KRKA, d.d., Novo mesto | Composition for the preparation of perindopril arginine granules, a method for their preparation and pharmaceutical composition comprising the granules |
SI26268A (sl) | 2021-11-18 | 2023-05-31 | Zupet Rok | Postopek za pripravo hidratirane oblike perindopril l-arginina |
CN114149357B (zh) * | 2021-12-29 | 2024-06-25 | 江苏嘉逸医药有限公司 | 一种γ晶型培哚普利精氨酸盐的制备方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2503155A2 (fr) * | 1980-10-02 | 1982-10-08 | Science Union & Cie | Nouveaux imino diacides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme |
FR2620703B1 (fr) * | 1987-09-17 | 1991-10-04 | Adir | Procede de synthese industrielle de l'acide perhydroindole carboxylique - 2(2s, 3as, 7as). application a la synthese de carboxyalkyl dipeptides |
JPH04352788A (ja) * | 1990-08-30 | 1992-12-07 | Kanebo Ltd | 新規キノリンカルボン酸誘導体、該化合物を有効成分とする抗菌剤および該化合物の製造方法 |
US6518423B1 (en) * | 1996-08-09 | 2003-02-11 | Eisai Co., Ltd. | Benzopiperidine derivatives |
FR2838648B1 (fr) * | 2002-04-18 | 2004-05-21 | Servier Lab | Nouveau sel de perindopril et les compositions pharmaceutiques qui le contiennent |
JP4402361B2 (ja) * | 2003-03-31 | 2010-01-20 | 大日本印刷株式会社 | 塩酸エピナスチンの結晶多形 |
WO2007020009A1 (en) * | 2005-08-12 | 2007-02-22 | Sandoz Ag | New crystalline form of perindopril erbumine |
FR2897866B1 (fr) * | 2006-02-28 | 2008-04-18 | Servier Lab | Forme cristalline alpha du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
FR2897865B1 (fr) * | 2006-02-28 | 2008-04-18 | Servier Lab | Forme cristalline beta du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
EP1864973A1 (en) * | 2006-06-09 | 2007-12-12 | Sochinaz SA | Process for the preparation of perindopril and salts thereof |
MX2010010853A (es) * | 2008-04-01 | 2011-02-23 | Lumavita Ag | Pentamicina altamente pura. |
EP2318365B1 (en) * | 2008-06-24 | 2015-08-12 | Mylan Laboratories Limited | Novel polymorphic forms of perindopril (l)-arginine and process for the preparation thereof |
AU2009212902A1 (en) * | 2008-09-03 | 2010-03-18 | Apotex Pharmachem Inc. | Amorphous form of an L-arginine salt of perindopril and processes of preparation thereof |
SI23001A (sl) * | 2009-03-20 | 2010-09-30 | Diagen@d@o@o | Nove soli perindoprila nov postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni |
CN102114017A (zh) * | 2011-01-05 | 2011-07-06 | 王定豪 | 包含氨氯地平和培哚普利的药物组合物及其应用 |
-
2012
- 2012-01-05 FR FR1200033A patent/FR2985511B1/fr not_active Expired - Fee Related
- 2012-12-18 PH PH12012000393A patent/PH12012000393B1/en unknown
- 2012-12-19 JO JOP/2012/0385A patent/JO3084B1/ar active
- 2012-12-19 CR CR20120655A patent/CR20120655A/es unknown
- 2012-12-19 SG SG2012093571A patent/SG192336A1/en unknown
- 2012-12-20 AU AU2012268815A patent/AU2012268815B2/en active Active
- 2012-12-20 PE PE2012002462A patent/PE20131327A1/es not_active Application Discontinuation
- 2012-12-20 IL IL223752A patent/IL223752A/en active IP Right Grant
- 2012-12-25 TN TNP2012000619A patent/TN2012000619A1/fr unknown
- 2012-12-26 CO CO12232915A patent/CO6700139A1/es unknown
- 2012-12-27 TW TW101150658A patent/TWI471307B/zh active
- 2012-12-27 MY MYPI2012701294A patent/MY176877A/en unknown
- 2012-12-27 UY UY0001034552A patent/UY34552A/es not_active Application Discontinuation
- 2012-12-27 NI NI201200194A patent/NI201200194A/es unknown
- 2012-12-28 MD MDA20120130A patent/MD4350C1/ro active IP Right Grant
- 2012-12-28 EA EA201201668A patent/EA022574B1/ru unknown
-
2013
- 2013-01-02 AP AP2013006657A patent/AP2013006657A0/xx unknown
- 2013-01-02 MA MA35526A patent/MA35002B1/fr unknown
- 2013-01-02 SA SA113340173A patent/SA113340173B1/ar unknown
- 2013-01-03 BR BR102013000161-9A patent/BR102013000161B1/pt active IP Right Grant
- 2013-01-03 CL CL2013000021A patent/CL2013000021A1/es unknown
- 2013-01-03 US US13/733,339 patent/US8835652B2/en active Active
- 2013-01-03 CA CA2800946A patent/CA2800946C/fr not_active Expired - Fee Related
- 2013-01-03 UA UAA201300119A patent/UA111334C2/uk unknown
- 2013-01-03 AR ARP130100015A patent/AR089631A1/es not_active Application Discontinuation
- 2013-01-04 CU CU2013000001A patent/CU20130001A7/es unknown
- 2013-01-04 SI SI201330001T patent/SI2612850T1/sl unknown
- 2013-01-04 EC ECSP13012365 patent/ECSP13012365A/es unknown
- 2013-01-04 WO PCT/FR2013/050018 patent/WO2013102741A1/fr active Application Filing
- 2013-01-04 PT PT131502965T patent/PT2612850E/pt unknown
- 2013-01-04 CN CN201310001506.XA patent/CN103193864B/zh active Active
- 2013-01-04 GE GEAP201312950A patent/GEP20146182B/en unknown
- 2013-01-04 ES ES13150296.5T patent/ES2439871T3/es active Active
- 2013-01-04 KR KR1020130001017A patent/KR101502945B1/ko active IP Right Grant
- 2013-01-04 PL PL13150296T patent/PL2612850T3/pl unknown
- 2013-01-04 JP JP2013000107A patent/JP5722923B2/ja active Active
- 2013-01-04 RS RS20130450A patent/RS53001B/en unknown
- 2013-01-04 DK DK13150296.5T patent/DK2612850T3/da active
- 2013-01-04 EP EP13150296.5A patent/EP2612850B1/fr active Active
- 2013-01-04 GT GT201300003A patent/GT201300003A/es unknown
- 2013-01-07 MX MX2013000013A patent/MX2013000013A/es active IP Right Grant
- 2013-12-04 CY CY20131101094T patent/CY1114704T1/el unknown
- 2013-12-05 HR HRP20131164AT patent/HRP20131164T1/hr unknown
-
2014
- 2014-01-06 HK HK14100092.1A patent/HK1187061A1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20131164T1 (hr) | Delta kristalni oblik argininske soli perindoprila, postupak za njegovu pripremu i farmaceutske pripravke koji ga sadrže | |
HRP20160644T1 (hr) | Kristalni oblik argininske soli perindoprila, postupak njegove priprave te farmaceutski pripravci koji ga sadrže | |
Mokale et al. | Synthesis and anti-inflammatory activity of some 3-(4, 6-disubtituted-2-thioxo-1, 2, 3, 4-tetrahydropyrimidin-5-yl) propanoic acid derivatives | |
HRP20100357T1 (hr) | Beta-kristalni oblik soli perindoprilarginina, postupak njegove priprave i farmaceutske smjese koje ga sadrže | |
HRP20160208T4 (hr) | Polimorfi dasatiniba i postupak za njihovu pripremu | |
Kamal et al. | Synthesis of 3, 3-diindolyl oxyindoles efficiently catalysed by FeCl3 and their in vitro evaluation for anticancer activity | |
Yusof et al. | Synthesis and characterisation a series of N-(3, 4-dichlorophenyl)-N′-(2, 3 and 4-methylbenzoyl) thiourea derivatives | |
HRP20140666T1 (hr) | Kristalni oblici derivata 2-tiazolil-4-kinolinil-oksi, snažnog hcv-inhibitora | |
HRP20170187T1 (hr) | Polimorfni oblici 2-(5-brom-4-(4-ciklopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio) octene kiseline i njihova upotreba | |
FI3057962T3 (fi) | Hydrokloridisuolamuoto ezh2-estoon | |
HRP20210507T1 (hr) | Supstituirani 5-fluoro-1h-pirazolopiridini u kristalnom obliku | |
HRP20191597T1 (hr) | Kristalni derivat 6,7-nezasićenog-7-karbamoil morfinana i postupak za njegovu proizvodnju | |
AR063351A1 (es) | DERIVADOS DE PURINA Y DE PIRIMIDINAS CONDENSADAS, COMPOSICION Y SU USO EN LA PREPARACIoN DE UN MEDICAMENTO PARA INHIBIR EL HSP90 EN UNA CELULA. | |
HRP20120066T1 (hr) | Kalijeva sol inhibitora hiv integraze | |
HRP20160540T1 (hr) | Sol i solvati jednog derivata tetrahidroizokinolina | |
FI2134702T4 (fi) | 6-[2-(metyylikarbamoyyli)fenyylisulfanyyli]-3-E-[2-(pyridiini-2-yyli)etenyyli]indatsolin kidemuotoja jotka soveltuvat nisäkkäiden poikkeavan solukasvun hoitamiseen | |
RU2014110399A (ru) | Кристаллические формы вгс протеазного ингибитора | |
NZ570533A (en) | Compounds useful as Selective androgen receptor modulators (SARM), in particular (2S)-3-(4-cyano-3-fluorophenoxy)-N-(4-cyano-3-methylphenyl)-2-hydroxy-2-methylpropionamide useful in hormonal therapy | |
JP2014522388A5 (hr) | ||
AR087683A1 (es) | N-[1-((6-cloropiridin-3-il)metil)piridin-2-(1h)-ilideno]-2,2,2-trifluoroacetamida, metodo para su preparacion y un intermediario para su sintesis | |
CA2654315A1 (en) | Substituted 4-aryl-1,4-dihydro-1,6-naphthyridines and their use | |
JP6160621B2 (ja) | ピロロキノリンキノンテトラアルカリ塩及びその結晶、これらの製造方法、並びに、組成物 | |
CA2647346A1 (en) | Malate salts, and polymorphs of (3s,5s)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid | |
HRP20161691T1 (hr) | Derivati ariletinila | |
NZ602648A (en) | Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers |